Role of brain inflammation in epileptogenesis

Yonsei Medical Journal

Volumn 49, Issue 1, 2008, Pages 1-18

  Choi, Jieun ^a,b   Koh, Sookyong ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b Seoul National University Boramae Hospital   (South Korea)

Author keywords

Astrocytes; Childhood; Cytokine; Epilepsy; Innate immunity; Microglia; Steroid

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q BINDING PROTEIN; COMPLEMENT COMPONENT C1QBETA; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CORTICOTROPIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FC RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MEASLES MUMPS RUBELLA VACCINE; PREDNISONE; PROSTAGLANDIN SYNTHASE; STEROID; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIMENTIN;

ACUTE GASTROENTERITIS; ASTROCYTE; ATONIC SEIZURE; AUTOIMMUNE DISEASE; BEHCET DISEASE; BLOOD BRAIN BARRIER; BRAIN INJURY; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; CHILDHOOD DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ENCEPHALITIS; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; EVIDENCE BASED MEDICINE; FEBRILE CONVULSION; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; HASHIMOTO DISEASE; HASHIMOTO ENCEPHALOPATHY; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOTHERAPY; INFANTILE SPASM; INFLUENZA VIRUS A; INTRACTABLE EPILEPSY; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; MICROGLIA; MYOCLONUS SEIZURE; NERVE CELL LESION; NEUROLOGIC DISEASE; NONHUMAN; RASMUSSEN SYNDROME; REVIEW; RISK FACTOR; SEIZURE; SPIKE WAVE; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; VACCINATION; VIRUS INFECTION;

ANIMALS; BLOOD-BRAIN BARRIER; CHRONIC DISEASE; ENCEPHALITIS; EPILEPSY; GENE EXPRESSION REGULATION; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 41949107443     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2008.49.1.1     Document Type: Review

References (155)

1. Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994;35 Suppl 2:S1-6.
2. Shinnar S, Pellock JM. Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol 2002;17 Suppl 1:S4-17.
3. Berg AT, Shinnar S, Levy SR, Testa FM. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia 1999;40:445-52.
4. Hauser WA HD. Epilepsy: Frequency, Causes and Consequences. New York: Demos; 1990.
5. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004;16:1-13.
6. Neuhaus J, Risau W, Wolburg H. Induction of blood-brain barrier characteristics in bovine brain endothelial cells by rat astroglial cells in transfilter coculture. Ann N Y Acad Sci 1991;633:578-80.
7. Krizanac-Bengez L, Mayberg MR, Janigro D. The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis and pathophysiology. Neurol Res 2004;26:846-53.
8. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 1994;6:341-60.
9. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, et al. Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol 1997;110:492-9.
10. Rider LG, Thapa PB, Del Beccaro MA, Gale JL, Foy HM, Farwell JR, et al. Cerebrospinal fluid analysis in children with seizures. Pediatr Emerg Care 1995;11:226-9.
11. Zhang W, Smith C, Howlett C, Stanimirovic D. Inflammatory activation of human brain endothelial cells by hypoxic astrocytes in vitro is mediated by IL-1beta. J Cereb Blood Flow Metab 2000;20:967-78.
12. deVeber G, Roach ES, Riela AR, Wiznitzer M. Stroke in children: recognition, treatment, and future directions. Semin Pediatr Neurol 2000;7:309-17.
13. Lynch JK, Nelson KE. Epidemiology of perinatal stroke. Curr Opin Pediatr 2001;13:499-505.
14. Kirkham FJ, DeBaun MR. Stroke in Children with Sickle Cell Disease. Curr Treat Options Neurol 2004;6: 357-75.
15. Aso K, Scher MS, Barmada MA. Cerebral infarcts and seizures in the neonate. J Child Neurol 1990;5:224-8.
16. Nelson KB, Lynch JK. Stroke in newborn infants. Lancet Neurol 2004;3:150-8.
17. Sreenan C, Bhargava R, Robertson CM. Cerebral infarction in the term newborn: clinical presentation and long-term outcome. J Pediatr 2000;137:351-5.
18. Golomb MR, Garg BP, Carvalho KS, Johnson CS, Williams LS. Perinatal stroke and the risk of developing childhood epilepsy. J Pediatr 2007;151:409-13, 413 e1-2.
19. Yang JS, Park YD, Hartlage PL. Seizures associated with stroke in childhood. Pediatr Neurol 1995;12:136-8.
20. Lanska MJ, Lanska DJ, Horwitz SJ, Aram DM. Presentation, clinical course, and outcome of childhood stroke. Pediatr Neurol 1991;7:333-41.
21. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995;26:1393-8.
22. Cutler SM, Pettus EH, Hoffman SW, Stein DG. Tapered progesterone withdrawal enhances behavioral and molecular recovery after traumatic brain injury. Exp Neurol 2005;195:423-9.
23. Lee T, von Scheven E, Sandborg C. Systemic lupus erythematosus and antiphospholipid syndrome in children and adolescents. Curr Opin Rheumatol 2001; 13:415-21.
24. Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995;99:397-401.
25. Liou HH, Wang CR, Chen CJ, Chen RC, Chuang CY, Chiang IP, et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996; 5:307-12.
26. Watemberg N, Greenstein D, Levine A. Encephalopathy associated with Hashimoto thyroiditis: pediatric perspective. J Child Neurol 2006;21:1-5.
27. Stratigos AJ, Laskaris G, Stratigos JD. Behçet's disease. Semin Neurol 1992;12:346-57.
28. Joseph FG, Scolding NJ. Neuro-Behçet's disease in Caucasians: a study of 22 patients. Eur J Neurol 2007; 14:174-80.
29. Mantegazza R, Bernasconi P, Baggi F, Spreafico R, Ragona F, Antozzi C, et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002;131:179-85.
30. Peltola JT, Haapala A, Isojärvi JI, Auvinen A, Palmio J, Latvala K, et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med 2000;109:712-7.
31. Eriksson K, Peltola J, Keränen T, Haapala AM, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res 2001;46:129-37.
32. Yoshimura K, Konishi T, Kotani H, Wakiguchi H, Kurashige T. Prevalence of positive anticardiolipin antibody in benign infantile convulsion. Brain Dev 2001;23:317-20.
33. Shrivastava A, Dwivedi S, Aggarwal A, Misra R. Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures. Lupus 2001; 10:45-50.
34. Nelson KB, Ellenberg JH. Predictors of epilepsy in children who have experienced febrile seizures. N Engl J Med 1976;295:1029-33.
35. Millichap JG. Studies in febrile seizures. I. Height of body temperature as a measure of the febrile-seizure threshold. Pediatrics 1959;23(1 Pt 1):76-85.
36. Virta M, Hurme M, Helminen M. Increased frequency of interleukin-1beta (-511) allele 2 in febrile seizures. Pediatr Neurol 2002;26:192-5.
37. Kanemoto K, Kawasaki J, Yuasa S, Kumaki T, Tomohiro O, Kaji R, et al. Increased frequency of interleukin-1beta-511T allele in patients with temporal lobe epilepsy, hippocampal sclerosis, and prolonged febrile convulsion. Epilepsia 2003;44:796-9.
38. Dubé C, Vezzani A, Behrens M, Bartfai T, Baram TZ. Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol 2005;57:152-5.
39. Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994;331:432-8.
40. Chiu SS, Tse CY, Lau YL, Peiris M. Influenza A infection is an important cause of febrile seizures. Pediatrics 2001;108:E63.
41. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics 1994;93:104-8.
42. Jee SH, Long CE, Schnabel KC, Sehgal N, Epstein LG, Hall CB. Risk of recurrent seizures after a primary human herpesvirus 6-induced febrile seizure. Pediatr Infect Dis J 1998;17:43-8.
43. Bertolani MF, Portolani M, Marotti F, Sabbattini AM, Chiossi C, Bandieri MR, et al. A study of childhood febrile convulsions with particular reference to HHV-6 infection: pathogenic considerations. Childs Nerv Syst 1996;12:534-9.
44. Kondo K, Nagafuji H, Hata A, Tomomori C, Yamanishi K. Association of human herpesvirus 6 infection of the central nervous system with recurrence of febrile convulsions. J Infect Dis 1993;167:1197-200.
45. Kawada J, Kimura H, Ito Y, Hara S, Iriyama M, Yoshikawa T, et al. Systemic cytokine responses in patients with influenza-associated encephalopathy. J Infect Dis 2003;188:690-8.
46. Masuyama T, Matsuo M, Ichimaru T, Ishii K, Tsuchiya K, Hamasaki Y. Possible contribution of interferon-alpha to febrile seizures in influenza. Pediatr Neurol 2002;27:289-92.
47. Vestergaard M, Hviid A, Madsen KM, Wohlfahrt J, Thorsen P, Schendel D, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004;292:351-7.
48. Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullcoly JP, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001;345:656-61.
49. Hirtz DG, Nelson KB, Ellenberg JH. Seizures following childhood immunizations. J Pediatr 1983;102:14-8.
50. Contino MF, Lebby T, Arcinue EL. Rotaviral gastrointestinal infection causing afebrile seizures in infancy and childbood. Am J Emerg Med 1994;12:94-5.
51. Nishimura S, Ushijima H, Nishimura S, Shiraishi H, Kanazawa C, Abe T, et al. Detection of rotavirus in cerebrospinal fluid and blood of patients with convulsions and gastroenteritis by means of the reverse transcription polymerase chain reaction. Brain Dev 1993;15:457-9.
52. Ushijima H, Bosu K, Abe T, Shinozaki T. Suspected rotavirus encephalitis. Arch Dis Child 1986;61:692-4.
53. Saulsbury FT, Winkelstein JA, Yolken RH. Chronic rotavirus infection in immunodeficiency. J Pediatr 1980; 97:61-5.
54. Chen HJ, Chen BS, Wang SF, Lai MH. Rotavirus gastroenteritis in children: a clinical study of 125 patients in Hsin-Tien area. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1991;32:73-8.
55. Prasad AN, Stafstrom CF, Holmes GL. Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids. Epilepsia 1996;37 Suppl 1:S81-95.
56. Klein R, Livingston S. The effect of adrenocorticotropic hormone in epilepsy. J Pediatr 1950;37:733-42.
57. Hrachovy RA, Frost JD Jr., Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. The Journal of pediatrics 1994;124(5 Pt 1):803-6.
58. Joëls M. Corticosteroid actions in the hippocampus. J Neuroendocrinol 2001;13:657-69.
59. Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther 2000;294:909-15.
60. Baram TZ, Hatalski CG. Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain. Trends Neurosci 1998;21:471-6.
61. Rasmussen T, Olszewski J, Lloydsmith D. Focal seizures due to chronic localized encephalitis. Neurology 1958; 8:435-45.
62. Bauer J, Elger CE, Hans VH, Schramm J, Urbach H, Lassmann H, et al. Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann Neurol 2007;62:67-80.
63. Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994;265:648-51.
64. Bahi-Buisson N, Villanueva V, Bulteau C, Delalande O, Dulac O, Chiron C, et al. Long term response to steroid therapy in Rasmussen encephalitis. Seizure 2007;16: 485-92.
65. Cowan LD, Hudson LS. The epidemiology and natural history of infantile spasms. J Child Neurol 1991;6:355-64.
66. Cowan LD, Bodensteiner JB, Leviton A, Doherty L. Prevalence of the epilepsies in children and adolescents. Epilepsia 1989;30:94-106.
67. Aicardi J. Infantile spasms and related syndromes. In: Aicardi J, editor. Epilepsy in children. New York: Raven Press; 1986.
68. Riikonen R. Infantile spasms: some new theoretical aspects. Epilepsia 1983;24:159-68.
69. Baram TZ. Pathophysiology of massive infantile spasms: perspective on the putative role of the brain adrenal axis. Ann Neurol 1993;33:231-6.
70. Low NL. Infantile spasms with mental retardation. II. Treatment with cortisone and adrenocorticotropin. Pediatrics 1958;22:1165-9.
71. Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004;62:1668-81.
72. Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996;97:375-9.
73. Hrachovy RA, Frost JD Jr., Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr 1983;103:641-5.
74. Lombroso CT. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983;24: 135-58.
75. Eisermann MM, DeLaRaillère A, Dellatolas G, Tozzi E, Nabbout R, Dulac O, et al. Infantile spasms in Down syndrome-effects of delayed anticonvulsive treatment. Epilepsy Res 2003;55:21-7.
76. Heiskala H. Community-based study of Lennox-Gastaut syndrome. Epilepsia 1997;38:526-31.
77. Sinclair DB. Prednisone therapy in pediatric epilepsy. Pediatr Neurol 2003;28:194-8.
78. Yamatogi Y, Ohtsuka Y, Ishida T, Ichiba N, Ishida S, Miyake S, et al. Treatment of the Lennox syndrome with ACTH: a clinical and electroencephalographic study. Brain Dev 1979;1:267-76.
79. Landau WM, Kleffner FR. Syndrome of acquired aphasia with convulsive disorder in children. Neurology 1957;7:523-30.
80. Sinclair DB, Snyder TJ. Corticosteroids for the treatment of Landau-kleffner syndrome and continuous spike-wave discharge during sleep. Pediatr Neurol 2005;32:300-6.
81. Tsuru T, Mori M, Mizuguchi M, Momoi MY. Effects of high-dose intravenous corticosteroid therapy in Landau-Kleffner syndrome. Pediatr Neurol 2000;22:145-7.
82. Tassinari CA BM, Dravet C, Dalla Bernardina B, Roger J. Epilepsy with continuous spikes and waves during slow sleep-otherwise described as epilepsy with electrical status epilepticus during slow sleep (ESES). In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence 3rd ed. London: John Libbey; 2002.
83. Gallagher S, Weiss S, Oram Cardy J, Humphries T, Harman KE, Menascu S. Efficacy of very high dose steroid treatment in a case of Landau-Kleffner syndrome. Dev Med Child Neurol 2006;48:766-9.
84. Snead OC 3rd, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology 1983;33:966-70.
85. Oguni H, Hayashi K, Awaya Y, Fukuyama Y, Osawa M. Severe myoclonic epilepsy in infants-a review based on the Tokyo Women's Medical University series of 84 cases. Brain Dev 2001;23:736-48.
86. Verhelst H, Boon P, Buyse G, Ceulemans B, D'Hooghe M, Meirleir LD, et al. Steroids in intractable childhood epilepsy: clinical experience and review of the literature. Seizure 2005;14:412-21.
87. Plata-Salamán CR, Ilyin SE, Turrin NP, Gayle D, Flynn MC, Romanovitch AE, et al. Findling modulates the IL-1beta system, TNF-alpha, TGF-beta1, and neuropeptide mRNAs in specific brain regions. Brain Res Mol brain Res 2000;75:248-58.
88. Zimmer LA, Ennis M, Shipley MT. Soman-induced seizures rapidly activate astrocytes and microglia in discrete brain regions. J Comp Neurol 1997;378:482-92.
89. Turrin NP, Rivest S. Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy. Neurobiol Dis 2004;16:321-34.
90. Jankowsky JL, Patterson PH. The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol 2001;63:125-49.
91. McNamara JO. Cellular and Molecular basis of epilepsy. J Neurosci 1994;14:3413-25.
92. Parent JM, Yu TW, Leibowitz RT, Geschwind DH, Sloviter RS, Lowenstein DH. Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. J Neurosci 1997;17:3727-38.
93. Koh S, Storey TW, Santos TC, Mian AY, Cole AJ. Early-life seizures in rats increase susceptibility to seizure-induced brain injury in adulthood. Neurology 1999;53:915-21.
94. Aloisi F. Immune function of microglia. Glia 2001;36: 165-79.
95. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-8.
96. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005;76:77-98.
97. Taniwaki Y, Kato M, Araki T, Kobayashi T. Microglial activation by epileptic activities through the propagation pathway of kainic acid-induced hippocampal seizures in the rat. Neurosci Lett 1996;217:29-32.
98. Rizzi M, Perego C, Aliprandi M, Richichi C, Ravizza T, Colella D, et al. Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiol Dis 2003;14:494-503.
99. Ravizza T, Rizzi M, Perego C, Richichi C, Velisková J, Moshé SL, et al. Inflammatory response and glia activation in developing rat hippocampus after status epilepticus. Epilepsia 2005;46 Suppl 5:113-7.
100. Fountain NB. Status epilepticus: risk factors and complications. Epilepsia 2000;41 Suppl 2:S23-30.
101. Henshall DC. Apoptosis signalling pathways in seizure-induced neuronal death and epilepsy. Biochem Soc Trans 2007;35(Pt 2):421-3.
102. Kang TC, Kim DS, Kwak SE, Kim JE, Won MH, Kim DW, et al. Epileptogenic roles of astroglial death and regeneration in the dentate gyros of experimental temporal lobe epilepsy. Glia 2006;54:258-71.
103. Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog Neurobiol 1999;57:563-81.
104. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 2003;100: 13632-7.
105. Borges K, Gearing M, McDermott DL, Smith AB, Almonte AG, Wainer BH, et al. Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp Neurol 2003;182:21-34.
106. Brandt C, Potschka H, Löscher W, Ebert U. N-methyl-D-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy. Neuroscience 2003;118:727-40.
107. Hanisch UK. Microglia as a source and target of cytokines. Glia 2002;40:140-55.
108. Aronica E, Gorter JA, Rozemuller AJ, Yankaya B, Troost D. Interleukin-1 beta down-regulates the expression of metabotropic glutamate receptor 5 in cultured human astrocytes. J Neuroimmunol 2005;160: 188-94.
109. Tilleux S, Berger J, Hermans E. Induction of astrogliosis by activated microglia is associated with a down-regulation of metabotropic glutamate receptor 5. J Neuroimmunol 2007;189:23-30.
110. Seifert G, Schilling K, Steinhäuser C. Astrocyte dysfunction in neurological disorders: a molecular perspectve. Nat Rev Neurosci 2006;7:194-206.
111. Gloor P. Epilepsy surgery New York: Raven Press; 1999.
112. Tian GF, Azmi H, Takano T, Xu Q, Peng W, Lin J, et al. An astrocytic basis of epilepsy. Nat Med 2005;11: 973-81.
113. O'Connor ER, Sontheimer H, Spencer DD, de Lanerolle NC Astrocytes from human hippocampal epileptogenic foci exhibit action potential-like responses. Epilepsia 1998;38:347-54.
114. Jørgensen MB, Finsen BR, Jensen MB, Castellano B, Diemer NH, Zimmer J. Microglial and astroglial reactions to ischemic and kainic acid-induced lesions of the adult rat hippocampal. Exp Neurol 1993; 120:70-88.
115. Somera-Molina KC, Robin B, Somera CA, Anderson C. Stine C, Koh S, et al. Glial activation links early-Life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation. Epilepsia 2007;48: 1785-800.
116. Seifert G, Schröder W, Hinterkeuser S, Schumacher T, Schramm J, Stemhäuser C. Changes in flip/flop splicing of astroglial AMPA receptors in human temporal lobe epilepsy. Epilepsia 2002;43 Suppl 5:162-7.
117. Schröder W, Hinterkeuser S, Seifert G, Schramm J, Jabs R, Wilkin GP, et al. Functional and molecular properties of human astrocytes in acute hippocampal slices obtained from patients with temporal lobe epilepsy. Epilepsia 2000;41 Suppl 6:S181-4.
118. Fedele DE, Gouder N, Guttinger M, Gabernet L, Scheurer L, Rülicke T, et al. Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. Brain 2005;128(Pt 10):2383-95.
119. Chung HKS. Encyclopedia of Basic Epilepsy Research. Burlington: Elsevier; in press.
120. Vezzani A, Conti M, De Luigi A, Ravizza T, Moneta D, Marchesi F, et al. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999;19:5054-65.
121. Oprica M, Eriksson C, Schultzberg M. Inflammatory mechanisms associated with brain damage induced by kainic acid with special reference to the interleukin-1 system. J Cell Mol Med 2003;7:127-40.
122. Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci U S A 2000;97:11534-9.
123. Bernardino L, Xapelli S, Silva AP, Jakobsen B, Poulsen FR, Oliveira CR, et al. Modulator effects of interleukin-1beta and tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures. J Neurosci 2005;25:6734-44.
124. Ravizza T, Gagliardi B, Noé F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008;29:142-60.
125. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, et al. Control of synaptic strength by glial TNFalpha. Science 2002;295:2282-5.
126. Viviani B, Bartesaghi S, Gardom F, Vezzani A, Behrens MM, Bartfai T, et al. Interleukin-1beta enhances MMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 2003;23:8692-700.
127. Ye ZC, Sontheimer H. Cytokine modulation of glial glutamate uptake: a possible involvement of nitric oxide. Neuroreport 1996;7:2181-5.
128. Bezzi P, Volterra A. A neuron-glia signalling network in the active brain. Curr Opin Neurobiol 2001;11:387-94.
129. Samland H, Huitron-Resendiz S, Masliah E, Criado J, Henriksen SJ, Campbell IL. Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J Neurosci Res 2003;73:176-87.
130. Patel HC, Boutin H, Allan SM. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann N Y Acad Sci 2003;992:39-47.
131. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 2000;23:618-25.
132. Panegyres PK, Hughes J. The neuroprotective effects of the recombinant interleukin-1 receptor antagonist rhIL-1ra after excitotoxic stimulation with kainic acid and its relationship to the amyloid precursor protein gene. J Neurol Sci 1998;154:123-32.
133. Giulian D, Li J, Li X, George J, Rutecki PA. The impact of microglia-derived cytokines upon gliosis in the CNS. Dev Neurosci 1994;16:128-36.
134. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996;2: 788-94.
135. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997;20:570-7.
136. Brett FM, Mizisin AP, Powell HC, Campbell IL. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 1995;54:766-75.
137. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A 1993;90: 10061-5.
138. Campbell IL. Transgenic mice and cytokine actions in the brain: bridging the gap between structural and functional neuropathology. Brain Res Brain Res Rev 1998;26:327-36.
139. Steffensen SC, Campbell IL, Henriksen SJ. Site-specific hippocauipal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice. Brain Res 1994;652:149-53.
140. Penkowa M, Molinero A, Carrasco J, Hidalgo J. Interleukin-6 deficiency reduces the brain irflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures. Neuroscience 2001,;102:805-18.
141. Brigande JV, Wieraszko A, Albert, MD, Balkema GW, Seyfried TN. Biochemical correlates of epilepsy in the El mouse: analysis of glial fibrillary acidic protein and gangliosides. J Neurochem 1992;58:752-60.
142. MG, Holmes GL, Seyfried TN. H, Hippocampal neurons and glia in epileptic EL inice. J Neurocytol 2002;31:681-92.
143. Ingram EM, Wiseman JW, Tessler S, Emson PC. Reduction of glial glutamate transporters in the parietal cortex and hippocampus of the EL mouse. J Neurochem 2001;79:564-75.
144. Sheng JG, Boop FA, Mrak RE, Griffin WS. Increased neuronal bet3-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. J Neurochem 1994;63:1872-9.
145. Crespel A, Coubes P, Rousset MC, Brana C, Rougier A, Rondouin G, et al. Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res 2002;952:159-69.
146. Maldonado M, Baybis M, Newman D, Kolson DL, Chen W, McKhann G 2nd, et al. Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis 2003;14:279-90.
147. Baranzini SE, Laxer K, Bollen A, Oksenberg JR. Gene expression analysis reveals altered brain transcription of glutamate receptors and inflammatory genes in a patient wiih chronic focal (Rasmussen's) encephalitis. J Neuroimmunol 2002;128:9-15.
148. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005;46: 1724-43.
149. Hulkkonen J, Koskikallio E, Rainesalo S, Keränen T, Hurme M, Peltola J. The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients. Epilepsy Res 2004;59:199-205.
150. Peltola J, Hurme M, Miettinen A, Keränen T. Elevated levels of interleukin-6 may occur in cerebrospinal fluid from patients with recent epileptic seizures. Epilepsy Res 1998;31:129-33.
151. Peltola J, Palmio J, Korhonen L, Suhonen J, Miettinen A, Hurme M, et al. Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res 2000;41: 205-11.
152. Kira R, Torisu H, Takemoto M, Nomura A, Sakai Y, Sanefuji M, et al. Genetic susceptibility to simple febrile seizures: interleukin-1beta promoter polymorphisms are associated with sporadic cases. Neurosci Lett 2005;384:239-44.
153. Beach TG, Woodhurst WB, MacDonald DB, Jones MW. Reactive microglia in hippocampal sclerosis associated with human temporal lobe epilepsy. Neurosci Lett 1995;191:27-30.
154. Aronica E, Gorter JA, Redeker S, Ramkema M, Spliet WG, van Rijen PC, et al. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilopsy. Neuropathol Appl Neurobiol 2005;31:280-91.
155. Boer K, Spliet WG, van Rijen PC, Redeker S, Troost D, Aronica E. Evidence of activated microglia in focal cortical dysplasia. J Neuroimmunol 2006,173:188-95.